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ABSTRACT 
Twenty percent of individuals at clinical high risk for psychosis (CHR-P) develop the disorder 
within two years. Extensive research has explored the factors that differentiate those who 
develop psychosis and those who do not, but the results are conflicting.  
The current systematic review and meta-analysis comprehensively addresses the consistency 
and magnitude of evidence for non-purely genetic risk and protective factors associated with 
the risk of developing psychosis in CHR-P individuals. Random effects meta-analyses, 
Standardised Mean Difference (SMD) and Odds Ratio (OR) were used, in combination with 
an established stratification of evidence that assesses the association of each factor and the 
onset of psychotic disorders (from class I, convincing evidence to class IV weak evidence), 
whilst controlling for several types of biases. 
128 original controlled studies relating to 26 factors were retrieved. No factors showed class I-
convincing evidence. Two further factors were associated with class II-highly suggestive 
evidence: attenuated positive psychotic symptoms (SMD = 0.348, 95%CI: 0.280, 0.415) and 
global functioning (SMD = -0.291, 95%CI: -0.370, -0.211). There was class III-suggestive 
evidence for negative psychotic symptoms (SMD = 0.393, 95%CI: 0.317, 0.469). There was 
either class IV-weak or no evidence for all other factors 
Our findings suggest that despite the large number of putative risk factors investigated in the 
literature, only attenuated positive psychotic symptoms, global functioning and negative 
psychotic symptoms show suggestive evidence or greater for association with transition to 
psychosis. The current findings may inform the refinement of clinical prediction models and 
precision medicine in this field. 
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INTRODUCTION 
The introduction of the first Clinical High Risk for Psychosis (CHR-P1) service, the PACE 
clinic2, has stimulated extensive research into psychosis prevention, to the point that the CHR-
P construct has become a key component of clinical services for early intervention3 (e.g. NICE 
guidelines4; NHS England Access and Waiting Time standard5). Simultaneously, some 
challenges have emerged, such as the need to refine the prediction of outcomes6. A key 
limitation is that the level of risk observed in CHR-P individuals is mostly accounted for by 
their sampling7. For example, when CHR-P criteria are applied to the general population, the 
level of risk of individuals meeting them is very low8–10. An additional problem is that there is 
poor knowledge in factors that modulate the level of risk in these individuals, because their 
identification and outcomes are entirely predicated on the basis of symptoms. However, 
symptoms represent an epiphenomenon of an underlying aetiopathology. In fact, the 
overarching model underlying the development of psychosis involves the culmination of 
genetic and environmental factors that can increase (risk factors) or decrease (protective 
factors) the likelihood of developing psychosis, as well as the interaction between them11,12. It 
is therefore essential to better understand the role of specific risk and protective factors in this 
area. Accordingly, we have recently published an umbrella review (a review of reviews) to 
quantitatively synthesise the existing literature on risk/protective factors for psychosis in the 
general population12. In a companion meta-analysis we confirmed that CHR-P individuals 
accumulate several environmental risk factors for psychosis, like childhood trauma, adverse 
life events and affective dysfunction, compared to controls, while the role of genetic and 
epigenetic risk factors in this group awaits clarification13. The effect of different risk/protective 
factors on the risk of developing and later transition to psychosis within individuals who have 
met CHR-P criteria has yet to be clarified at a meta-analytical level.  
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Despite much research into risk/protective factors potentially associated with transition to 
psychosis in CHR-P samples, the studies are often small, underpowered or inconsistent in their 
results. Meta-analytical methods can address these issues. Reviewing risk/protective factors 
for the development of psychosis within CHR-P samples is relevant twofold. Firstly, while we 
know that 20% of CHR-P individuals transition to psychosis within two years14, we are 
currently unable to predict who will transition and who will not. Greater understanding of the 
specific risk/protective factors that increase risk of transition at the individual subject level will 
allow for improved prognostication. Secondly, some factors may be potentially modifiable, 
therefore allowing for novel, individualised therapeutic strategies, thereby improving primary 
indicated prevention of psychosis.  
 
To our knowledge, this study is the first meta-analysis to quantitatively synthesise the evidence 
for risk/protective factors for developing psychosis in CHR-P individuals. The primary aim is 
to systematically review the evidence for risk/protective factors within the CHR-P population 
and to provide a meta-analytical summary of their magnitude, direction of effect and 
consistency, controlling for several biases (e.g. small study effect and excess significance bias). 
The latter point will be achieved by complementing the standard pairwise meta-analysis with 
the use of validated criteria that have been developed for umbrella reviews12,15–17 to stratify the 
evidence of association between risk/protective factors and outcomes.  
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METHODS 
Search strategies 
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)18 and 
Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines19 were adhered 
to throughout to achieve high quality of reporting (eTables 1 & 2). Details of the protocol for 
systematic review were registered on PROSPERO (CRD42017077470).  
 
A two-step systematic search of the literature was performed by two independent researchers 
(T.R. & O.B.B.) to identify relevant studies investigating the effect of risk and protective 
factors for transition to psychosis in CHR-P individuals.  
 
The Ovid database by Wolters Kluwer (including MEDLINE, EMBASE and PsycINFO) was 
searched. Full search strategy including keywords can be seen in eMethods 1. The search was 
extended from inception until 13th May 2018.  
 
Inclusion criteria 
Articles meeting the inclusion criteria for the current systematic review and meta-analysis 
were: a) original articles, written in English b) cohort studies examining the association 
between risk/protective factors and psychotic disorders in the CHR-P population c) included 
CHR-P individuals defined by standard psychometric instruments: Comprehensive 
Assessment of At Risk Mental States (CAARMS)20; Brief Psychiatric Rating Scale (BPRS)21; 
Structured Interview for Psychosis-Risk Syndromes (SIPS)22; Basel Screening Instrument for 
Psychosis (BSIP)23  d) reported transitions to a psychotic disorder as a key outcome measure, 
defined according to standard international Diagnostic and Statistical Manual of Mental 
Disorders (DSM) or International Statistical Classification of Diseases and Related Health 
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Problems (ICD) criteria -any version- e) reported follow-up of at least one year, based on meta-
analytical evidence suggesting that shorter follow-up times may be associated with infrequent 
events24 (transitions to psychosis) resulting in underpowered studies. 
 
Exclusion criteria 
In line with our previous work12,13 we excluded biomarkers, purely genetic factors and 
cognitive factors, because these would require a different and specific meta-analytical 
approach. Furthermore, despite advances in genetic understanding in this field (e.g. polygenic 
risk scores), our understanding is still relatively limited, while the role of biomarkers25 and 
cognition26 has already been meta-analysed by our group. As such, we excluded: (a) conference 
abstracts, reviews, case-reports, cross-sectional studies and case-control studies, (c) purely 
genetic factors, (d) biomarkers or cognitive factors, (d) studies using CHR-P definitions other 
than those listed above. 
 
Data extraction 
Data extraction was done independently by two investigators (T.R. & O.B.B.). Any 
discrepancies were resolved in consensus meetings with another author (D.O.) under the 
supervision of a senior researcher (P.F.P.). Data selection and extraction was based on a 
systematic approach that is further detailed in eMethods 2. For continuous factors we also 
considered the mean baseline value in the transition and mean baseline value in the non-
transition group. The factors were grouped in the following domains that had no influence on 
the statistical analyses, in line with previous studies in this area: sociodemographic/parental 
factors, later factors, antecedents and symptom scores/clinical factors12,27,28. Details of risk of 
bias assessment can be found in eMethods 3. 
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Statistical analysis 
Standard pairwise meta-analysis 
The meta-analytical effect-size measure was Odds Ratio (OR) for dichotomous factors and 
Standardised Mean Difference (SMD) for continuous factors. An OR greater than 1 or an SMD 
greater than 0 indicated that the factor was associated with an increased likelihood of psychotic 
disorders. OR lower than 1 or SMD lower than 0 indicated that the factor was associated with 
a reduced likelihood of psychotic disorders, i.e. it was protective. 
The meta-analysis investigated each specific risk/protective factor without providing pooled 
estimates (within-subgroup summary effects) as they were felt to be clinically uninterpretable. 
In the case of studies reporting different definitions of the same outcome measure (e.g. 
reporting both CAARMS and BPRS for symptom scores), a mean effect size and an estimate 
of the variance based on the calculated weight of the included definitions was computed.  
Random-effects models were used to control for heterogeneity.  
 
Hierarchical classification of the evidence 
In line with previous studies employing umbrella review criteria for classifying the evidence 
of association between risk/protective factors and health disorders12,15–17, analyses included: a) 
an Egger test to assess small‐study effects that lead to potential reporting or publication bias30; 
and b) a test of excess significance bias31. The test of excess significance bias consisted of a 
binomial test to compare the observed vs. the expected number of studies yielding statistically 
significant results. This expected number was calculated as the sum of the statistical power of 
the studies. Small‐study effects and excess significance bias were claimed at one‐sided p values 
<0.05, as in previous studies15. 
The levels of evidence of the associations between putative risk/protective factors and 
transition to psychotic disorder were then classified according to the guidelines for umbrella 
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reviews32: convincing (class I) when number of cases >1000, p < 10−6, I2 < 50%, 95% 
prediction interval excluding the null, no small‐study effects, and no excess significance bias; 
highly suggestive (class II) when number of cases >1000, p < 10−6, largest study with a 
statistically significant effect, and class I criteria not met; suggestive (class III) when number 
of cases >1000, p<10−3, and class I‐II criteria not met; weak (class IV) when p < 0.05 and class 
I‐III criteria not met; non‐significant when p > 0.05. 
Finally, a sensitivity analysis was conducted for the factors classified as class I‐III by using 
only prospective studies. Prospective studies allow one to address the temporality of the 
association, thus dealing with the problem of reverse causation16,17. 
Analyses were carried out using Comprehensive Meta-Analysis Version 3 and STATA 14. 
 
RESULTS 
Database 
Overall, 77,045 records were searched, 259 were screened and 128 were eligible (see Figure 
1). The eligible articles were published between 1998 (shortly after the first CHR-P service 
was established) and 13th May 2018.   
Overall, the 128 eligible studies comprising 17,967 patients reported on 26 putative 
risk/protective factors of transition to psychotic disorders for CHR-P individuals (eTable 3). 
These 26 putative risk/protective factors were separated for descriptive purposes into four 
categories: sociodemographic/parental factors, later factors, antecedents and symptom 
scores/clinical factors. 
 
The number of cases was greater than 1,000 for five factors (19.2%). 11 out of the 26 analysed 
factors had significant associations with psychosis (34.6%), with eight (30.8%) reaching 
p<0.001 (Tables 1-4). Nine factors (34.6%) presented a large heterogeneity (I2>50%). 
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Additionally, the evidence for small-study effects was noted for ten out of the 23 factors 
(43.5%) with enough studies for this to be conducted. 
 
Convincing evidence for association with transition to psychosis 
There were no risk or protective factors with a convincing level of evidence (class I: number 
of cases >1000, p < 10−6, I2 < 50%, 95% prediction interval excluding the null, no small‐study 
effects, and no excess significance bias) for an association with risk of transition to psychosis 
(Tables 1-4). 
 
Highly suggestive evidence for association with transition to psychosis 
There was highly suggestive evidence (class II: >1000 cases, p<0.001, largest study with 
statistically significant effect, and class I criteria not met) that two further factions are 
associated with increased (attenuated positive psychotic symptoms; SMD = 0.348, 95%CI: 
0.280, 0.415) and decreased (global functioning; SMD = -0.291, 95%CI: -0.370, -0.211) 
transition risk, respectively (Table 4). 
 
Suggestive evidence for association with transition to psychosis 
There was suggestive evidence (class III: >1000 cases, p<0.01, class I/II criteria not met) for 
negative psychotic symptoms (SMD = 0.393, 95%CI: 0.317, 0.469) increasing risk of transition 
to psychosis (Table 4). This changed little when analyses were run without total negative 
SIPS/SOPS scores or questionable negative SIPS/SOPS items (SMD = 0.369, 95%CI: 
0.280,0.458) 
 
Weak evidence of association with transition to psychosis 
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There was weak evidence (class IV: p < 0.05 and class I‐III criteria not met) of an association 
with increased risk of transition to psychosis for one sociodemographic/parental factor (male 
gender, OR = 1.178, 95%CI: 1.034, 1.341), three later factors (stress/trauma (OR = 1.146, 
95%CI: 1.038, 1.265), living status (OR = 1.557, 95%CI: 1.085, 2.232), employment (OR = 
0.553, 95%CI: 0.400, 0.765)), one antecedent (right handedness (OR = 1.602, 95%CI: 1.041, 
2.465) and three symptom scores/clinical factors (disorganised/cognitive symptoms (SMD = 
0.317, 95%CI: 0.172, 0.461), general symptoms (SMD = 0.227, 95%CI: 0.122, 0.332), total 
symptom scores (SMD = 0.307, 95%CI: 0.148, 0.467) (Tables 1-4). 
 
There was no evidence of association with transition to psychotic disorders for all other 16 
factors (see Tables 1-4) 
 
No change in classification of evidence of associations after sensitivity analysis 
No factors with suggestive evidence or greater (attenuated positive psychotic symptoms, global 
functioning and negative psychotic symptoms) were downgraded following removal of studies 
with retrospective designs (eTable 6) or studies not employing ICD or DSM criteria to 
determine transition status in addition to CHR-P instruments. Only one study was considered 
to have a retrospective design with all other studies having prospective designs.  
 
DISCUSSION 
To the best of our knowledge, this is the first meta-analysis of risk and protective factors for 
transition to psychotic disorders in CHR-P individuals that includes a robust hierarchical 
classification of the published evidence. After two decades of CHR-P research, it was 
imperative to advance knowledge by screening the available evidence against robust criteria. 
Overall, 128 individual studies comprising 17,967 patients and 26 factors potentially associated 
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with transition to psychosis were included. There were no factors with convincing evidence 
(class I) for an association with risk of transition. Attenuated positive psychotic symptoms and 
global functioning were characterised by highly suggestive evidence (class II) with negative 
psychotic symptoms supported by suggestive evidence (class III).  
 
The main finding of this meta-analysis is that, although a large number of risk/protective 
factors for transition to psychotic disorders have been evaluated in numerous CHR-P studies, 
none show convincing evidence with few having suggestive or stronger support. This likely 
reflects a research field which is fragmented, heterogeneous and that still represents a small 
niche to display a scalable impact. For example, the availability of different CHR-P assessment 
instruments is associated with disagreement in the designation of cases or definition of their 
outcomes33. The recent introduction of the DSM-5 category of Attenuated Psychosis Syndrome 
has further complicated the psychometric comparability of CHR-P cases34. On a similar note, 
the heterogeneity of the CHR-P group has already been demonstrated at both diagnostic33,35 
and prognostic14,36 level, to the point that stratification of this group has been suggested in a 
previous issue of this journal1,37. The limited scalability and impact of the CHR-P field has also 
received empirical demonstration on several lines of evidence. Since the CHR-P literature is 
characterised by relatively small studies with infrequent events (transition to psychosis), the 
meta-analytical findings did not survive the strict criteria for the classification of evidence, 
with it being particularly rare for factors to have over 1000 cases. While this criterion is 
intended to identify robust epidemiological risk/protective factors, the CHR-P field is per se 
epidemiologically weak38, because it is characterised by substantial sampling biases7. A 
striking example of these points is the recent evidence showing that only about 5% of 
individuals who will develop psychosis can be detected at their CHR-P stage in secondary 
mental health care39,40. Overall, this finding clearly indicates that future CHR-P research should 
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be collaborative, scalable and better harmonised in terms of assessment of intake criteria and 
outcomes. Ongoing international projects such as PSYSCAN41, PRONIA42 and North 
American Prodrome Longitudinal Study (NAPLS)43 which have all been integrated in the 
HARMONY project may reach the critical mass that is needed to better identify risk/protective 
factors that modulate transition to psychosis with convincing evidence. 
 
Despite these caveats, we found highly suggestive evidence that attenuated positive psychotic 
symptoms and global functioning are directly and inversely associated with the risk of 
transitioning to psychosis, respectively. These findings are unsurprising. First, severity of 
positive symptoms is the main factor in deciding whether an individual meets CHR-P criteria 
and develops a first episode of psychosis. CHR-P individuals with higher attenuated positive 
psychotic symptom scores at baseline are closer to the threshold of transition and therefore do 
not require the same degree of symptom progression as others with less severe symptoms. 
Although there is consensus that current CHR-P tools are biased towards detecting attenuated 
positive psychotic symptoms1,44,45 the P1-P4 subscales on the CAARMS and the P1-P5 
subscales on the SIPS actually contain a variety of attenuated symptoms beyond positive 
ones1,33. For example, obsessive thoughts, derealisation and depersonalisation experiences as 
well as time perception alterations. Fine-grained data is not available: most studies did not 
report the single severity and frequency scores of the specific CAARMS/SIPS subscales (see 
eTable 3). Moreover, this is true of randomised controlled trials44. When these data were 
available, sensitivity analyses confirmed that all individual attenuated positive psychotic 
symptoms remained significant with the exception of grandiose ideas (eTable 4). Moreover, 
even when splitting attenuated positive psychotic symptoms into individual items on 
assessments, this may not be fine-grained enough for optimal prediction. Previous important 
studies have shown that auditory hallucinations may be highly predictive of transition to 
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psychosis, while visual hallucinations may be associated with a reduced risk46. Unfortunately, 
this level of detail in data is rarely reported in primary literature, so further analysis was not 
possible. Second, previous research has already shown that higher functioning at baseline is 
associated with reduced risk of transition47,48. Although impaired global functioning is variably 
ascertained by CHR-P assessment instruments33, it is one of the most robust predictors in this 
field. Machine-learning prediction models determined social outcomes at 1 year in up to 83% 
of patients in clinical high-risk states and 70% of patients with recent-onset depression49. We 
also found suggestive evidence for a direct association of negative psychotic symptom severity 
and risk of transition to psychosis. This factor would have met the criteria for highly suggestive 
evidence, however, the largest study50 did not show a statistically significant effect. Negative 
psychotic symptoms of at least moderate severity are incredibly common among CHR-P 
individuals with 82% endorsing at least one negative psychotic symptom51 and with high 
prevalence (41%) of comorbid affective disorders52. Negative psychotic symptoms along with 
impaired baseline global functioning, are typically the driving force for individuals seeking 
help at CHR-P services53 and their persistence leads to poor outcomes54.  
 
A number of other factors were found to have weak evidence of an association with transition 
to psychosis in CHR-P individuals, with the key restriction for a greater class of evidence being 
fewer than 1000 cases. Stress/trauma increased risk of psychosis within CHR-P individuals. 
Our previous meta-analyses found that trauma is a key risk factor for psychosis in the general 
population12 and a risk factor for CHR-P status13. Male gender was also seen to increase 
psychosis risk within CHR-P samples. Our previous meta-analyses found it to be a risk factor 
for psychosis in the general population12 and for CHR-P status13, however with greater effect 
sizes than in this analysis. One potential explanation for this lies in the fact that the current 
analysis focuses on an enriched sample for these factors, thus diluting the variance. This is 
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likely to be true of other factors traditionally associated with psychosis, such as cannabis use, 
that were found to have non-significant associations in this analysis. Moreover, cannabis use 
has typically been assessed in a binary fashion, measuring if individuals have ever used before, 
despite degree of exposure seemingly being key to the association with psychosis in both the 
general population55 and in CHR-P56. We also found that employment is protective, reducing 
the risk of transitioning to psychosis in CHR-P individuals. Employment is an indirect measure, 
contingent on other factors such as symptoms and global functioning57. Right handedness also 
had a weak association with increased psychosis risk within CHR-P individuals. This effect 
was in the opposite direction to in the general population12. However, as many included studies 
were fairly small, interpretation should be taken cautiously. Other clinical factors, particularly 
disorganised and cognitive symptoms, were found to have a weak association with psychosis. 
Their impact can be particularly relevant within the clinical subgroup of brief limited 
intermittent psychotic symptoms (BLIPS), where disorganising or dangerous features have 
been associated with an extremely high risk of transition35.  
 
The above findings can advance clinical knowledge in this area. First, they can be used to 
improve the prognosis of outcomes. At present, CHR-P assessment tools have outstanding 
sensitivity but lack specificity6,8 i.e. they are adept at ruling out psychosis risk but are inefficient 
at ruling it in. Accordingly, recent studies have suggested using refined clinical prediction 
models to improve prognostic accuracy39,40,58. The risk and protective factors identified in class 
II and III of evidence in the current meta-analysis could represent core benchmarks for 
developing future clinical prediction models. Some of the factors identified by our analysis 
have already been incorporated into risk calculators for CHR-P individuals. For example, the 
NAPLS calculator includes higher levels of attenuated positive psychotic symptoms (unusual 
thought content and suspiciousness) and greater decline in social functioning58, while another 
 16 
calculator similarly includes attenuated positive psychotic symptoms (unusual thought content, 
visual perceptual abnormalities and disorganisation), negative psychotic symptoms (social 
anhedonia and ideational richness) and global functioning59. Prognostic accuracy can be further 
improved when clinical prediction models are combined with biomarker60 or cognitive58 data 
in a sequential assessment framework. Stepped assessments offer the advantage to optimise the 
resources reserving more complex assessment to those already filtered through simpler 
procedures25. Our analysis also reveals key risk/protective factors that at the moment present 
with weak evidence for association and that awaits further validation through larger cohort 
studies. Improved understanding of which CHR-P individuals are more likely to transition to 
psychosis would also lead to some potential clinical benefits such as easiest detection of those 
more at risk and faster referrals to early detection services, thereby reducing the duration of 
untreated psychosis and improving outcomes61–68. Finally, advancing knowledge on factors 
that modulate the onset of psychosis within CHR-P samples can inform preventive 
interventions, as some of these may be potentially modifiable. Available preventive 
interventions do not seem to be more effective, compared to each other, nor benefit the severity 
of attenuated positive psychotic symptoms44, negative psychotic symptoms69 or global 
functioning70 that have been identified as class II-III. While the meta-analytical picture is 
currently bleak, due to the infancy of the field there have been very few randomised controlled 
trials in CHR-P. Further studies and increased focus on the effects of these treatments on the 
severity of attenuated positive psychotic symptoms, negative symptoms and global functioning 
are key to the progression of the field. Since there is no evidence that current preventive 
treatments can reliably modify the risk of developing psychosis in CHR-P samples71, 
experimental therapeutics in this area are urgently needed and should be the focus of the next 
generation of research.  
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The main limitation of the current analysis is that the CHR-P literature is still relatively small 
compared to other areas of psychiatry. For example, our umbrella review12 assessing risk and 
protective factors for psychosis was able to draw on 50 years of evidence, and yet was only 
able to find two factors with a convincing level of evidence. Although the CHR-P field only 
has the past 20 years to draw evidence from, there are still two factors with highly suggestive 
levels of evidence. This may be due to the fact that the CHR-P paradigm is intrinsically 
embedded in prospective cohort studies. Future studies in this area have the potential to move 
class III factors into higher classes and therefore to progress and improve the evidence base. 
Similarly, as already noted in the umbrella review12, the vast majority of factors assessed in the 
current literature are risk factors, rather than protective factors. Protective factors like self-
esteem, social support and resilience may be better assessed in future primary research studies 
to identify what may aid psychosis prevention. Another limitation is the clinical heterogeneity 
of the CHR-P population. Within this, there are people with attenuated psychotic symptoms 
(APS), BLIPS and genetic risk and deterioration syndrome (GRD)14. Furthermore, there are 
differences between APSS (attenuated positive symptom syndrome) as defined by the SIPS, 
APS as defined by the CAARMS, DSM-5 APS, as well as others34. However, these differences 
are limited at the meta-analytical level8 with the majority of risk (around 60%) for developing 
psychosis in CHR-P individuals being accumulated before the assessment is performed7,72. As 
such, there is a high degree of variance within the CHR-P cohorts in these studies, which can 
dilute the effect of certain risk factors as they can affect these subgroups differently. Future 
studies would be wise to subdivide and sufficiently power their samples to ascertain the 
differential effects of risk/protective factors on these subgroups1. Finally, there were only a few 
studies available to contribute data for some factors, and as for any other meta-analysis that 
has adopted our classification criteria of evidence, we cannot exclude that other risk/protective 
factors may be identified and published in the near future. 
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CONCLUSIONS 
Severity of attenuated positive psychotic symptoms and low global functioning show 
convincing evidence, while severity of negative psychotic symptoms shows suggestive 
evidence for increasing transition risk in CHR-P individuals. These factors should be 
considered as benchmarks by future clinical prediction models and key targets of new 
experimental therapeutics. 
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Figure 1 – PRISMA flowchart outlining study selection process 
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Table 1 – Level of evidence for the association of sociodemographic/parental factors and psychotic disorders 
Risk factor K Random effects measures, 
ES (95% CI) 
N P random 
effects 
I2 (p) PI (95% CI) LS SSE/ESB eOR CE 
Male gender 66 OR, 1.178 (1.034, 1.341) 1732 0.014 13.983 (0.174) 0.7810 – 1.7760 Yes No/No 1.178 IV 
Urbanicity 4 OR, 1.548 (0.584, 4.104) 59 0.380 69.435 (0.020)  -5.0916 – 8.1876 Yes Yes/No 1.548 ns 
Age 61 SMD, -0.035 (-0.102, 0.033) 1776 0.313 32.012 (0.009) -0.3260 – 0.2560 No No/No 0.939 ns 
Parental socioeconomic status 14 OR, 0.955 (0.739, 1.234) 444 0.725 37.519 (0.077) -0.2389 – 2.1489 No No/No 0.955 ns 
Migrant status 2 OR, 0.932 (0.544, 1.596) 113 0.797 33.457 (0.220) N/A No N/A/No 0.932 ns 
Non-white ethnicity 19 OR, 0.949 (0.604, 1.203) 714 0.665 25.641 (0.143) -0.4990 – 1.8070 No No/No 0.949 ns 
Education 25 OR, 0.872 (0.718, 1.059) 795 0.167 40.038 (0.021)  -0.4570 – 1.6630 No No/No 0.872 ns 
k – number of samples for each factor, ES – effect size, N – number of cases, PI – prediction interval, CI – confidence interval, SSE – small study effect, ESB – excess 
significance bias, LS – largest study with significant effect, eOR – equivalent odds ratio, CE – class of evidence, OR – odds ratio, SMD – standardised mean difference, 
NA – not assessable, ns – not significant 
Higher classes of evidence for associations are emphasised with darker blue. Bold text is indicative of why factors are not a higher CE 
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Table 2 - Level of evidence for the association of later factors and psychotic disorders 
Risk factor K Random effects measures, 
ES (95% CI) 
N P random 
effects 
I2 (p) PI LS SSE/ESB eOR CE 
Stress/trauma 11 OR, 1.146 (1.038, 1.265) 454 <10-6 35.681 (0.113) 0.9015 – 1.3905 No No/No 1.146 IV 
Living status 10 OR, 1.557 (1.085, 2.232) 289 0.016 0.000 (0.537) 0.6547 – 2.4593 No No/No 1.557 IV 
Employment 7 OR, 0.553 (0.400, 0.765) 268 <10-4 0.000 (0.870) 0.4000 – 0.7650 No No/No 0.553 IV 
Stigma 2 OR, 4.604 (0.825, 25.701) 21 0.082 70.619 (0.065) N/A Yes N/A/Yes 4.604 ns 
Substance misuse1 12 OR, 1.322 (0.965, 1.813) 382 0.082 13.760 (0.310) 0.1734 - 2.4706 No No/No 1.322 ns 
Tobacco use 10 OR, 1.285 (0.904, 1.826) 233 0.162 14.907 (0.306) 0.0342 – 2.5358 No No/No 1.285 ns 
Cannabis use 23 OR, 1.189 (0.954, 1.480) 759 0.123 35.848 (0.046) 0.0217 - 2.3563 No Yes/No 1.189 ns 
Brain injury 2 OR, 0.888 (0.561, 1.405) 104 0.611 0.000 (0.665) N/A No N/A/No 0.888 ns 
Alcohol 10 OR, 0.834 (0.626, 1.110) 472 0.212 29.747 (0.171) -0.3278 – 1.9958 Yes No/No 0.834 ns 
k – number of samples for each factor, ES – effect size, N – number of cases, PI – prediction interval, CI – confidence interval, SSE – small study effect, ESB – excess 
significance bias, LS – largest study with significant effect, eOR – equivalent odds ratio, CE – class of evidence, OR – odds ratio, SMD – standardised mean difference, NA 
– not assessable, ns – not significant 
1 Substance misuse refers to substances not covered by other factors i.e. does not refer to alcohol, cannabis or tobacco use 
Higher classes of evidence for associations are emphasised with darker blue. Bold text is indicative of why factors are not a higher CE 
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Table 3 - Level of evidence for the association of antecedents and psychotic disorders 
Risk factor K Random effects measures, 
ES (95% CI) 
N P random 
effects 
I2 (p) PI LS SSE/ESB eOR CE 
Right handedness 16 OR, 1.602 (1.041, 2.465) 354 0.032 0.000 (0.663) 0.6576 – 2.5464 No No/No 1.602 IV 
Perinatal complications 6 OR, 2.058 (0.893, 4.746) 129 0.090 87.785 (0.000) -2.5694 – 6.6854 Yes No/No 2.058 ns 
Height 5 SMD, 0.157 (-0.047, 0.361) 138 0.132 0.000 (0.824) -0.1742 – 0.4882 No Yes/No 1.329 ns 
BMI 3 SMD, -0.060 (-0.440, 0.320) 26 0.756 0.000 (0.709) -2.5234 – 2.4034 No Yes/No 0.897 ns 
k – number of samples for each factor, ES – effect size, N – number of cases, PI – prediction interval, CI – confidence interval, SSE – small study effect, ESB – excess 
significance bias, LS – largest study with significant effect, eOR – equivalent odds ratio, CE – class of evidence, OR – odds ratio, SMD – standardised mean difference, NA 
– not assessable, ns – not significant 
Higher classes of evidence for associations are emphasised with darker blue. Bold text is indicative of why factors are not a higher CE 
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Table 4 - Level of evidence for the association of symptom scores/clinical factors and psychotic disorders 
Risk factor K Random effects measures, 
ES (95% CI) 
N P random 
effects 
I2 (p) PI LS SSE/ESB eOR CE 
Attenuated positive psychotic 
symptoms 
49 SMD, 0.348 (0.280, 0.415) 1163 <10-6 69.344 
(<0.001) 
-0.0010 – 0.6970 Yes Yes/No 2.563 II 
Global functioning 49 SMD, -0.291 (-0.370, -0.211) 1560 <10-6 76.205 
(<0.001) 
-0.7146 – 0.1330 Yes Yes/No 0.590 II 
Negative psychotic symptoms 49 SMD, 0.393 (0.317, 0.469) 1374 <10-6 62.872 
(<0.001) 
-0.0090 – 0.7770 No Yes/No 2.681 III 
Disorganised/cognitive symptoms 18 SMD, 0.317 (0.172, 0.461) 503 <10-6 77.067 
(<0.001) 
-0.1810 – 0.8150 No Yes/No 2.485 IV 
Total symptoms score 29 SMD, 0.307 (0.148, 0.467) 675 <10-6 72.282 
(<0.001) 
-0.4403 – 1.0543 No Yes/No 1.743 IV 
General symptoms 21 SMD, 0.227 (0.122, 0.332) 541 <10-4 62.307 
(<0.001) 
-0.1190 – 0.5730 No Yes/No 2.271 IV 
Co-morbidity 19 OR, 1.134 (0.926, 1.389) 587 0.223 54.470 (0.002) 0.4282 – 1.8392 No No/No 1.134 ns 
Basic symptoms 2 SMD, 0.267 (-0.027, 0.562) 115 0.075 43.119 (0.185) N/A Yes N/A/No 1.621 ns 
k – number of samples for each factor, ES – effect size, N – number of cases, PI – prediction interval, CI – confidence interval, SSE – small study effect, ESB – excess 
significance bias, LS – largest study with significant effect, eOR – equivalent odds ratio, CE – class of evidence, OR – odds ratio, SMD – standardised mean difference, NA – 
not assessable, ns – not significant 
Higher classes of evidence for associations are emphasised with darker blue. Bold text is indicative of why factors are not a higher CE 
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